liu et al , blood, 2003 , 101, 3014. patent wo 02/24218 a1; us 2004/0038907 a1
DESCRIPTION
The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), the new physiological regulator of angiogenesis. Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1. Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP). purified from bone marrow (10 - 50 µg/kg tissue) - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/1.jpg)
Liu et al, Blood, 2003, 101, 3014.
Patent WO 02/24218 A1; US 2004/0038907 A1
The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), the new physiological regulator of angiogenesis
![Page 2: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/2.jpg)
CO2H
NNH
HN
OCO2H
O
NH2
O
NH
HOO
• purified from bone marrow (10 - 50 µg/kg tissue)
• present in the blood at concentrations of 10-9 M
• structure determined by AA analysis, 1D and 2D 1H-RMN, FAB-MS, MS-MS
• inhibitor of hematopoietic stem cell proliferation
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP)
Proc Natl Acad Sci USA, 1989, 86, 779
![Page 3: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/3.jpg)
Leukemia, 1989, 4, 315
AcSDKP is a physiological regulator of hematopoiesis(in vivo administration of anti-AcSDKP antibodies
triggers hematopoietic stem cell into S-phase)
AcSDKP + antiAcSDKP (incubated overnight)complex =
control
% o
f C
FU
-S in
S-p
has
e50
anti-AcSDKP
![Page 4: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/4.jpg)
Go S S
Go Go
S
S
Hematopoieticstem cell
Chemo- or radiothera
py
chemo- or radiothera
py
+ proliferation inhibitor
Bone marrow aplasia
Cancer cell
Cell survival
(immunodeficiency, hemorrhages…)
cell proliferation
Bone marrow toxicity => major limiting factor in the treatment of cancer
![Page 5: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/5.jpg)
AraC : 30 mg/kg/inj s.c. 1x day, during 15d AcSDKP : 100 ng/inj i.p. 1x day, during 15d
100
50
control AraC Arac + AcSDKP (LD 90)
% mice survival
(simult)
(2h post)
(6h post)
(8h post)
Ann NY Acad Sci, 1991, 628, 126.
In vivo, AcSDKP inhibits hematopoietic stem cell (CFU-S) proliferation and increases the survival of mice given
lethal doses of chemotherapy (AraC)
Proc Nat Acad Sci USA, 1989, 86, 779.
40
20
% CFU-S en S
nat. synth.
control AraC AraC + AcSDKP
(100 ng/mouse)
![Page 6: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/6.jpg)
AcSDKP (0.5 g/kg/day), i.v. infusionfrom -24h to +1h with regard to time of irradiation
Ann Hematol, 1997, 74, 117.
In vivo protective effect of AcSDKP against the myelotoxicity
of total irradiation (300 cGy)
+ AcSDKP
irradiated controlG
ran
ulo
cyte
s / m
m3
10 20 30 40 50days after irradiation
10000 + AcSDKP
irradiatedcontrol
% o
f su
rviv
al
100
![Page 7: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/7.jpg)
->> anticancer drugs :- AraC (cytosine arabinoside)- CTX (cyclophosphamide)- 5-FU (5-fluorouracil)- doxorubicine->> irradiation
->> anticancer drugs :- AraC- AZT (azidothymidine)- AstaZ (mafosfamide)->> phototherapy->> hyperthermy
In vivo In vitro
Myeloprotective effect of AcSDKP
AcSDKP => new myeloprotective agent
Clinical application:in vivo: radio- and chemotherapyin vitro: bone marrow purging before autologous grafting
![Page 8: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/8.jpg)
Phase I: devoided of toxicity (continuous infusion), excellent tolerance
Phase II: myeloprotective effect of AcSDKP in cancer patients undergoing monochemotherapy (AraC or ifosphamide)
- decrease of neutropenia - decrease of leucopenia
Clinical trials of AcSDKP “Goralatide”(Beaufour Laboratories - IPSEN Biotech)
![Page 9: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/9.jpg)
Biosynthesis
AcSDKP
Receptor studyMechanism of action
Catabolisme
Analogues
![Page 10: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/10.jpg)
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP)BIOSYNTHESIS
Thymosin 4 (T4) = metabolic precursor of AcSDKP ?
- intracellular co-localisation of T4 and AcSDKP- inhibits proliferation of hematopoietic stem cells-[3H]T4 + bone marrow cells => [3H]AcSDKP
AcSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
43 AA
AcSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES?
AcSDKPDMAEIEKFD-prolylendopeptidase
AcSDKP
T4
FEBS Lett, 1990, 274, 30.Cell Prolif, 1996, 29, 437.
![Page 11: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/11.jpg)
T4
stimulation of angiogenesis
increased in cancer tissues
AcSDKP role in angiogenesis?
Question
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP)BIOSYNTHESIS
![Page 12: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/12.jpg)
AcSD*KPAngiotensin I-Converting Enzyme (ACE)
AcSD + *KP
*K + P
Hg2+ sensitive peptidase
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP)CATABOLISMCATABOLISM
AcSDKP = physiological substrate of N-active site of ACE
C-active siteACE
Ang I -> Ang IIbradykinin -> inactive form
AcSDKP -> AcSD + KP
N-active site
Biochem J, 1993, 296, 373.J Biol Chem, 1995, 270, 3656.
![Page 13: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/13.jpg)
2 4 6 8
placebo0
3
6
9
1 2
1 5
time (hours)
captopril
In vivo (humans)
captopril(ACE inhibitor)
AcS
DK
P i
n b
loo
d [
nM
]
ACE
ACE inhibitors stimulation of angiogenesis
AcSDKP role in angiogenesis ?
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP)CATABOLISMCATABOLISM
J Clin Invest, 1996, 97, 839.
![Page 14: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/14.jpg)
EC receptor binding
EC activation (MMPs production)
EC proliferation
EC migration
ECM remodeling
Tube formation
Loop formation
Vascular stabilisation
Angiogenesis QuickTime™ et un décompresseur
GIF sont requis pour visualisercette image.
![Page 15: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/15.jpg)
Angiogenesis QuickTime™ et un décompresseur
GIF sont requis pour visualisercette image.
![Page 16: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/16.jpg)
AcSDKP is produced and secreted by endothelial cells
.
0
0.5
1.0
1.5
2.0
2.5
3.0
0
1
2
3
4
5
time of culture (days)0 1 2 3 4 7 8 10
cell n
um
be
r x 1
06
AcS
DK
P [
pm
ol/
10
6 c
ells
]
![Page 17: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/17.jpg)
AcSDKP enhances the secretion of active form of matrix metalloproteinase (MMP-1)
and stimulates migration of endothelial cells
1 2 3
control 10-11 10-9
AcSDKP [M]
MM
P-1
co
nte
nt
(ng
/106
cells
)
+ 84%
**
*
20
40
60
80
MMP-1
**
****
***
1
2
*
57 %
control 10-13 10-11 10-9 10-7 10-5
AcSDKP [M]
mig
rati
on
sc o
r e
Migration
![Page 18: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/18.jpg)
AcSDKP enhances endothelial cell proliferation
![Page 19: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/19.jpg)
AcSDKP stimulates formation of vascular capillaries by endothelial cells
Assay of tube formation on Matrigel measures both the migration
and differentiation of endothelial cells into capillary-like structures
80
20
40
60
% in
crea
se in
tu
be
form
atio
n
**
**
**
****
*
**
10-15 10-13 10-11 10-9 10-7 10-5 FGF-2 AcSDKP [M] (1ng/ml)
![Page 20: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/20.jpg)
In vitro, AcSDKP promotes an angiogenic response of endothelial cells
AcSDKP Receptor binding
EC activation
EC proliferation
Directional migration
ECM remodeling
Tube formation
Loop formation
Vascular stabilisation
(increase in the secreted active form of MMP-1)
![Page 21: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/21.jpg)
In vivo, AcSDKP stimulates the neovascularisation in the chicken embryo chorioallantoic membrane
(CAM)
control + AcSDKP 30- 40 embryos/dose2 days of incubation
***
***
***
30
20
10
0.002 0.02 0.2 2 200 2
**
pmol/cm2
AcSDKPAcSDDKP
% i
nc
rea
se
in
ve
ss
els
nu
mb
er
![Page 22: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/22.jpg)
Day 28
control treated with AcSDKP
In vivo, AcSDKP stimulates the neovascularisation in abdominal muscle in the rat
Day 7
AcSDKP i.m. (5 µg/kg/injection) during 5 days
![Page 23: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/23.jpg)
In vivo, AcSDKP stimulates corneal neovascularisation
control tumor spheroid tumor spheroid + AcSDKP
control spheroid spheroid + AcSDKP
Administration of AcSDKP (800 g/kg/day) via osmotic mini-pumps was started on the day of operation andcontinued for 10 days.
+200%
(9L-gliosarcoma cell spheroid)
Am J Physiol, 2004, 287, 2099.
![Page 24: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/24.jpg)
In vivo, AcSDKP induces blood vessel invasion
Matrigel alone or containing AcSDKP injected s.c. in rats. Histological analysis
of Matrigel plugsperformed at day 7 %
in
crea
se
in v
esse
ls n
um
ber
100
200
AcSDKP [M]
* *
*
010-9 10-7 10-5
AcSDKP stimulates vascular infiltration into Matrigel plugs implanted subcutaneously in rats
+ control
+ AcSDKP
![Page 25: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/25.jpg)
QuickTime™ et un décompresseurGIF sont requis pour visualiser
cette image.
Angiogenesis
Brain stroke
Wound healing
Limb arterial occlusive disease
Cancer
![Page 26: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/26.jpg)
Therapeutic effects of AcSDKP1. Brain stroke
*
cortex sub-cortex brain
0.5
1.5
1.0
+saline+AcSDKP
VO
L T
2 d
8 / d
2AcSDKP reduces the extent of
ischemic region in subcortical part of brain
Focal cerebral ischemia inducedexperimentally in the rat by occlusion of the middle cerebral artery (90 min)
The volumes of the injured ischemic areas were monitored
using magnetic resonance imaging (MRI)
AcSDKP infusion (osmotic mini-pumps)
7 days
![Page 27: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/27.jpg)
Therapeutic effects of AcSDKP2. Hindlimb ischemia
Limb ischemia, in patients with arterial occlusive disease in the leg, is a major health problem
surgically induced ischemia in mice (femoral artery occlusion)
AcSDKP infusion (osmotic mini-pumps)
3 weeks
- high-definition iliac microangiography- assessment of capillary density (immunohistochemistry) - laser Doppler perfusion imaging (DPI) (extent of blood flow = functional evidence for changes in vascularisation)
![Page 28: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/28.jpg)
Isch
N.Isch
AcSDKPcontrol
AcSDKP administration significantly increasesthe angiogenic score in the ischemic limb
2. Hindlimb ischemia
An
gio
gra
ph
ic s
core
(Isc
h./N
.Isch
.)
0.5
1
1.5
**
control AcSDKP
![Page 29: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/29.jpg)
AcSDKP induces revascularisation in brain and limb ischemic tissues
and ameliorates the outcome of ischemic disease as shown by
improvement of blood flow measured by Doppler (limb ischemia)
Therapeutic effects of AcSDKPCurative effect on the ischemic damages in brain and hindlimb
Circulation, 2004, submittedPatent WO 02/24218 A1; US 2004/0038907 A1
![Page 30: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/30.jpg)
Objective: N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a natural inhibitor of pluripotent hematopoietic stem cell proliferation, has been suggested as capable of promoting an angiogenic response. We studied whether Ac-SDKP 1) stimulates endothelial cell proliferation, migration and tube formation; 2) enhances angiogenic response in the rat cornea following implantation of a tumor spheroid; and
3) increases capillary density in rat hearts with myocardial infarction (MI). Methods and Results: 1) In vitro: an immortal BALB/c mouse aortic endothelial 22106 cell line was used to determine the effects of Ac-SDKPon endothelial cell proliferation and migration and tube formation. 2) In vivo: : a 9L-gliosarcoma cell spheroid (250-300 µm in diameter) was
implanted in the rat cornea and vehicle or Ac-SDKP (800 µg/kg/day) infused i.p. via osmotic mini-pump. 3) Myocardial capillary density was studied in rats with MI given either vehicle or Ac-SDKP. We found that Ac-SDKP: 1) stimulated endothelial cell proliferation and migration and tube formation in a dose-dependent manner;
2) enhanced corneal neovascularization; and 3) increased myocardial capillary density. Conclusions: Endothelial cell proliferation and angiogenesis stimulated by AcSDKP could be beneficial in cardiovascular diseases such as hypertension and MI. Furthermore, since AcSDKP is mainly cleaved by ACE, it may partially mediate the cardioprotective effect of ACE inhibitors.
![Page 31: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/31.jpg)
AcSDKP increases capillary density in rat hearts with myocardial infarction (MI)
MI was induced by ligation of left anterior descending coronary artery. AcSDKP was infused ip via osmotic mini-pumps 7 days before MI and continuing for 4 months.
Sham-MI saline AcSDKP MI
+ 75%
Therapeutic effects of AcSDKP
![Page 32: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/32.jpg)
Ex vivo, AcSDKP accelerates the process of wound healing
of human skin explants injured with UVB irradiation (10J/cm2)
control + AcSDKP
keratin 14
fibronectin
Therapeutic effects of AcSDKP3. Wound healing
![Page 33: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/33.jpg)
control + AcSDKP
In vivo, AcSDKP rescues the impaired vascularisation of ischemic experimental skin flaps and reduces
their necrosis
control+ AcSDKP
AcSDKP injected s.c. for 5 days following operation.
Evaluation of skin flap survival and skin flap vascularisation at day 7
Therapeutic effects of AcSDKP4. Postinjury tissue repair in surgical skin flap with ischemia
QuickTime™ et un décompresseurTIFF (LZW) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (LZW) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (LZW) sont requis pour visualiser
cette image.
![Page 34: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/34.jpg)
Therapeutic effects of AcSDKPCurative effect on the skin injury
AcSDKP actively participates in the repair of cutaneous damages:
-> enhanced healing of injured explants of human skin
-> accelerated wound healing of experimentally induced pseudo-ulcers in rats
-> improvement of the viability of ischemic skin flaps in rats (promoting of post-operative angiogenesis)
Wound repair and regeneration, 2004 (submitted)Patent WO 02/24218 A1; US 2004/0038907 A1
These findings identify AcSDKP as a new tissue-repair agents andsuggest its potential clinical use for the management of skin woundsand as adjuvant to healing in plastic and reconstutive surgery
![Page 35: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/35.jpg)
Structure-activity relationship study
Conception of new molecules with biological efficacy higher than that displayed by AcSDKP
A I M
![Page 36: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/36.jpg)
short sequence
stereoisomers:
modification of AA lateral chains
modification of N- terminus
Ac Ser-DAsp-Lys-Pro-OH, AcDSer-DAsp-DLys-DPro-
OH
Analogues of AcSDKP
Ac-Ser-Asp-Lys-Pro-OH
Succinyl
Homo-Seror Ala Glu
Arg or Ornithine
![Page 37: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/37.jpg)
In vitro and in vivo evaluation of analogues’ angiogenic activity
Analogues of AcSDKP coll. J. Thierry, ICSN
Dimers (tail-head or head-head):Ac-Ser-Asp-Lys-Pro-Ser-Asp-Lys-Pro-OH
HO-Pro-Lys-Asp-Ser-Succinyl-Ser-Asp-Lys-Pro-OH
Analogues resistant to proteolysis
Ac-N-Ser-Asp-Lys-Pro-OH
(CH2NH)Pro-NH2
cyclic peptide
![Page 38: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/38.jpg)
In vivo effect of AcSDKP analogues on neovascularisation in CAM
10-10 10-9 10-8 10-7 10-5 [M]0.002 0.02 0.2 2 200 pmoles/cm2
AcSDKP
AcSDKP-NH2 dimer head-head
AcSDDKPAcDSerDAspDLysDPro
% i
ncr
eas
e in
vas
cul a
r d
ensi
ty
1 2 3 4 5
10
20
30
![Page 39: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/39.jpg)
Localisation of AcSDKP receptor on endothelial cell:
flow cytometry and confocal microscopy with:
MAP (Multiple Antigen Peptide)
coumarin- SDKP labelled with fluorescein
autoradiography with [3H]AcSDKP
Lys-Ala-OH
Lys
Lys
Lys
Lys
Lys
Lys
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP receptor
ex c . = 3 74 n m
e m . = 470 n m
= 1 7x1 03
O ON
C O -SDKP
![Page 40: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/40.jpg)
Localization of AcSDKP receptor
10-9M MAP 10-9M MAP + 1000x AcSDKP
Incubation of human dermal microvascular endothelial cells with MAP for 5 min at 37°C.
Lys-Ala-OH
Lys
Lys
Lys
Lys
Lys
Lys
AcSDKPAcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
AcSDKP
MAP
ex
em
Specific nuclear bindingof AcSDKP
![Page 41: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/41.jpg)
exc. = 374 nm
em. = 470 nm
= 17x103
O ON
CO-
Coum-SDKP
SDKP
Localization of AcSDKP receptor
Project: to characterise the AcSDKP receptor and then to design new ligands offering an improved affinity for this receptor and consequently an improved angiogenic efficacy
Incubation of murine bone marrow microvascular endothelial cells with coum-AcSDKP for 5 min at 37°C.
![Page 42: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/42.jpg)
Nuclear localisation of thymosin 4(confocal section of fibroblasts NIH-3T3 following microinjection of labelled T4)
J Cell Sci, 2004, 117, 5333.
![Page 43: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/43.jpg)
Objectives
To provide a basic understanding of the mechanisms involved in angiogenesis
Developement of new drugs which will stimulate deficient angiogenesis (e.g. in hindlimb, cerebral and cardiac ischemia,wound healing, skin graft…)
![Page 44: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/44.jpg)
AcSDKP
Links between biological effects of AcSDKP
Stimulation of angiogenesis
Hematoprotection duringradio- and chemotherapy
Enhancement of bone marrow graft
???
![Page 45: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/45.jpg)
Role of AcSDKP in cancer angiogenesis ?
is there a correlation betweenlevels of endogenous AcSDKP
and the developement of neoplastic diseases ?
QuickTime™ et un décompresseurPhoto - JPEG sont requis pour visualiser
cette image.
AcSDKP
![Page 46: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/46.jpg)
Angiogenesis is essential not only for solid tumor growth but also plays a crucial role in hematological malignancies
Hematological disorders (leukemia, lymphoma, myeloma, myeloplastic syndromes…)
were shown to be angiogenesis-dependent and revealsignificantly increased neovascularity in the bone marrow
Role of AcSDKP in cancer angiogenesis ?
![Page 47: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/47.jpg)
Increased level of AcSDKP in plasma of leukemic mice
SA2, SA7, SA9, SA10 => post-irradiation AML(different proportion of blast cells)
AcS
DK
P (
pm
ol/m
l)
control SA2 SA7 SA9 SA10 mice leukemic mice
0
10
20
** **
**
**p < 0.001**6-fold increase
![Page 48: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/48.jpg)
Concentration of AcSDKP in plasma of SA9 miceincreases with the progression of disease
time following transplantation of leukemic cells
AcS
DK
P (
pm
ol/m
l)
0 day 4 day 6 day 7 day 80
2
4
6
8
10
12
** **
**
**
0 day 4 day 6 day 7 day 8
![Page 49: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/49.jpg)
Level of AcSDKP in bone marrow cells of leukemic mice
0
1
2
time following transplantation of leukemic cells
0 day 4 day 6 day 7 day 8
NS
SA9
**
**
**
0
1
2
3
4
AcS
DK
P (
pm
ol/1
06 cel
ls)
control SA2 SA7 SA9 SA10 mice leukemic mice
**
** **
**
6-fold increase
![Page 50: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/50.jpg)
Concentration of AcSDKPin bone marrow cell supernatants of leukemic mice
1,0
2,0
AcS
DK
P (
pm
ol/1
06 cel
ls)
control SA2 SA7 SA9 SA10 mice leukemic mice
NS
****
**
0,5
1,0
1,5
0 day 4 day 6 day 7 day 8time following transplantation
of leukemic cells
SA9
**
**
**
**
![Page 51: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/51.jpg)
NBM
SA9 BM
Expression of AcSDKP in mouse normal and leukemic (SA9) bone marrow
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
![Page 52: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/52.jpg)
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
Expression of AcSDKP in mouse normal and leukemic (SA2) spleen cells
normal spleen
SA2 spleen
![Page 53: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/53.jpg)
Concentration of AcSDKP in human plasma(coll. Prof. T. Robak)
control AML CLM 0
1
2
3
4
5
6
n = 34
+ 203 %A
cSD
KP
(p
mol
/ml)
+ 61 %
n = 33 n = 65
(acute myeloid (chronic lymphocytic leukemia) leukemia)
![Page 54: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/54.jpg)
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
Expression of AcSDKP in human leukemic (CLM) bone marrow
chronic lymphocytic leukemia
![Page 55: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/55.jpg)
normal cancer
Expression of AcSDKP in human ovarium tissue
![Page 56: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/56.jpg)
cancer prostate
normal prostate
Expression of AcSDKP in human prostate
![Page 57: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/57.jpg)
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
QuickTime™ et un décompresseurTIFF (non compressé) sont requis pour visualiser
cette image.
(coll. Profs Kuzdak, Komorowski, Stepien)
normal lobus papillary thyroid cancer lobus
Expression of AcSDKP in human thyroid
![Page 58: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/58.jpg)
0
2
4
6
8
10
12
peripheric blood: 1.59 + 0.45tumor blood: 4.34 + 2.98
AcS
DK
P [
nM
]
8 11 12 13 15 23 24 25 26 27 29 30N° of patient
Thy
roid
B-c
ell l
ymph
oma
Thy
roid
lym
phom
aThy
nom
a in
vasi
vum
Concentration of AcSDKP in plasma of patients with malignant tumors of thyroid(coll. Profs Kuzdak, Komorowski, Stepien)
![Page 59: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/59.jpg)
Ac S
DK
P [
nM
]
2
4
6
8
10
12
peripheric bloodtumor blood
papillary thyroid thyroid thyroid thynoma cancer lymphoma B-cell lymphoma invasivum
Concentration of AcSDKP in plasma of patients with malignant tumors of thyroid(coll. Profs Kuzdak, Komorowski, Stepien)
6 fold
3 fold
5 fold
2 fold increasen = 18
![Page 60: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/60.jpg)
Role of AcSDKP in cancer angiogenesis ?
AcSDKP, a potent stimulator of angiogenesis in vivo, may contribute to leukemia and solid tumor angiogenesis.
This finding permit to hypothesise that AcSDKP expression may be critical factor
for leukemia and solid tumor expansion
Leukemia & Lymphoma, in preparationBr J Cancer, in preparation
![Page 61: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/61.jpg)
Objectives
To provide a basic understanding of the mechanisms involved in angiogenesis
Developement of new drugs which will stimulate deficient angiogenesis (e.g. in hindlimb, cerebral and cardiac ischemia,wound healing, skin graft…) or to inhibit it in the case of cancer
![Page 62: Liu et al , Blood, 2003 , 101, 3014. Patent WO 02/24218 A1; US 2004/0038907 A1](https://reader035.vdocuments.net/reader035/viewer/2022062221/56813358550346895d9a6c44/html5/thumbnails/62.jpg)
AcSDKP
Links between biological effects of AcSDKP
Stimulation of angiogenesis
Hematoprotection duringradio- and chemotherapy
Enhancement of bone marrow graft
???